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Abstract
Background: Reverse phase protein arrays (RPPA) emerged as a useful experimental platform to analyze biological 
samples in a high-throughput format. Different signal detection methods have been described to generate a 
quantitative readout on RPPA including the use of fluorescently labeled antibodies. Increasing the sensitivity of RPPA 
approaches is important since many signaling proteins or posttranslational modifications are present at a low level.
Results: A new antibody-mediated signal amplification (AMSA) strategy relying on sequential incubation steps with 
fluorescently-labeled secondary antibodies reactive against each other is introduced here. The signal quantification is 
performed in the near-infrared range. The RPPA-based analysis of 14 endogenous proteins in seven different cell lines 
demonstrated a strong correlation (r = 0.89) between AMSA and standard NIR detection. Probing serial dilutions of 
human cancer cell lines with different primary antibodies demonstrated that the new amplification approach 
improved the limit of detection especially for low abundant target proteins.
Conclusions: Antibody-mediated signal amplification is a convenient and cost-effective approach for the robust and 
specific quantification of low abundant proteins on RPPAs. Contrasting other amplification approaches it allows target 
protein detection over a large linear range.
Background
In recent years reverse phase protein arrays (RPPA) have
proven themselves as useful experimental platform for
the validation of biomarker candidate proteins in biologi-
cal and clinical samples [1-6]. RPPA are considerably
faster than conventional techniques such as mass spec-
trometry, western blotting, 2-D PAGE, and allow the
analysis of hundreds of samples in parallel. In addition,
measurements can be made with high accuracy and
reproducibility. The basic idea of RPPA implies that all
samples are spotted in parallel on solid-phase carriers.
Samples can be printed either as serial dilutions or in a
single concentration but as multiple replicate spots [7].
The detection of a specific protein or a certain phospho-
rylation site is carried out with a single and highly specific
antibody per slide, and the fraction of captured antibod-
ies is mostly visualized with secondary antibodies.
Recently, near infrared fluorescence-based detection was
reported as useful for reverse phase protein microarrays
[8,9]. Routine applications involved analyzing the activa-
tion status of signaling pathways [10], protein profiling
after RNAi-based silencing experiments [11], as well as of
tumor biopsies [12,13].
Critical for the outcome of RPPA-based measurements
are first of all the sensitivity and specificity of primary
antibodies but also of the signal detection method since
samples are delivered as tiny droplets on solid phase car-
riers and no further separation steps are possible. In addi-
tion, proteins of interest may be expressed at a low level
and their visualization requires means for signal amplifi-
cation. Tyramide signal amplification (TSA) has been
widely applied to increase the sensitivity of RPPAs [14-
18]. However, TSA linked with a streptavidin-biotin strat-
egy can produce unspecific signals that may interfere
with the signal of interest [19].
The fluorescence-based signal amplification method
introduced here avoids the use of the streptavidin-biotin
system and achieves signal amplification by using fluores-
cently labeled antibodies from two different species
selected to recognize the respective other species. With
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increasing numbers of alternating incubation cycles the
intensity of fluorescent signals was stronger and a highly
sensitive quantitative read-out was obtained (Figure 1).
This approach was named antibody-mediated signal
amplification (AMSA). Working steps were adapted to a
fully automated procedure. AMSA was demonstrated to
be a robust and specific approach to increase the sensitiv-
ity of the recently reported IP AQ stra tegy [8]. Using a
spike-in experiment with recombinant JNK1-protein the
lower limit of detection (LOD) was reduced almost 10-
fold compared to standard near infrared fluorescence
readout using the IPAQ strategy. Additional experiments
demonstrated that AMSA is especially useful to improve
the linear range of signal detection for proteins expressed
at a low level.
Methods
Cell culture conditions and cell lysis
Human colon cancer cell lines HCT15 (CCL-225),
HCT116 (CCL-247), H508 (CCL-253), SW620 (CCL-
227), HT29 (HTB-38), RKO (CLR-2577), and SW480
(CCL-228) as well as the breast cancer cell lines
HCC1954 (CRL-2338), MDA-MB-231 (HTB-26), BT-474
(HTB-20), SK-BR-3 (HTB-30), MCF-7 (HTB-22), and
T47D (HTB-133) were obtained from American Type
Culture Collection (Manassas, USA). Breast cancer cell
lines were cultivated under conditions recommended by
ATCC (ATCC serum and medium annotation, http://
www.lgcpromochem-atcc.com). All colon cancer cell
lines were cultivated in RPMI 1640 medium (ATCC) con-
taining 10% FCS and 1% Pen/Strep (both Invitrogen,
Karlsruhe, Germany). Cell lines were grown until 90%
confluence and split 3 times per week. For lysis, cultured
cells were incubated with trypsin (Sigma, Munich, Ger-
many) and lysed in 1 ml M-PER (Pierce, Rockford, USA)
containing 2 mM ortho-sodium-vanadate (Sigma), 10
mM NaF, and Complete mini protease inhibitor. The pro-
tein concentration was determined in duplicate by BCA
Protein Assay (Pierce). Protein lysates were stored at -
80°C until use.
Tissue preparation
Prostate tissue samples were collected at Martini-Clinic,
Prostate Cancer Center (University Medical Center Ham-
burg-Eppendorf, Germany). Samples were acquired dur-
ing radical prostatectomy and sectioned with a
microtome. One slice of prostate tumor tissue was pro-
cessed per experiment. Mouse liver tissue and collected
prostate tissue were lysed with modified T-PER buffer
(Pierce). 10 μl of lysis buffer were used per mg of tissue
sample. Samples were homogenized 4 minutes with a tis-
suelyser (Qiagen, Hilden, Germany). Cell debris was sub-
sequently pelleted (12 minutes, 13000 rpm) and the
supernatant was passed through a Qiashredder tube
(Qiagen).
Printing of protein microarrays
Protein lysates and spike-in experiments with recombi-
nant His-tagged JNK (Invitrogen) were serially diluted
with protein lysis buffer. To prepare samples for inkjet-
spotting using the Sprint (ArrayJet, Roslin, Scotland) an
equal volume of spotting-buffer (50% (v/v) Glycerol and
0.05% (w/v) Triton × 100 in ddH20) was added to each
sample resulting in a final glycerol concentration of 25%.
A pin tool spotter, the 2470 Arrayer (Aushon, Billerica,
MA, USA), was employed to print serial dilutions of cell
line lysates (SW480, HCT15, HCT116, SW620, HT29,
HCC1954, MDA-MB-231, BT-474, SK-BR-3, MCF-7 and
T47D). Dilution series comprised 14 steps and were pro-
duced by diluting with lysis buffer by 33% per step. Sam-
ples were printed directly after adding Tween20 to a final
concentration of 0.05% (v/v).
Samples were always printed onto nitrocellulose coated
glass-slides (Grace Biolabs, Bent, OR, USA). Each spot
corresponded to a final drop volume of 0.3 nl (pin tool
spotter) or 0.6 nl (non-contact inkjet printer). The spot-
to-spot distance was set to 320 μm and the spot diameter
was 140 μm. Slides were stored at 4°C and used within a
week.
Near infrared target protein detection on microarrays
Slides were blocked with a mixture of 33% Odyssey
blocking buffer (LI-COR, Lincoln, USA), 1% BSA, and
0,02% NP40 in PBS overnight at 4°C. Primary antibodies
were diluted in a buffer with background-reducing com-
ponents (Dako, Glostrup, Denmark). Slides were incu-
bated for 2 h with primary antibodies and subsequently
immersed in wash buffer (1x PBS, 0.02% NP40 and 0.02%
SDS) four times for 5 minutes. Next, slides were incu-
bated with Alexa680-conjugated secondary antibody
(Invitrogen, dilution 1:8,000) for 30 minutes. Washing
was performed as described above. All washing and incu-
bation steps were carried out at RT with gentle shaking.
Finally, slides were rinsed in water and air-dried at room
temperature.
The following detection antibodies were employed for
western blotting and RPPA-based analysis: JNK (BD Bio-
sciences, San Jose, USA), CDK4, Cyclin D1, GSK, PP2AA,
PP2AB, PDK1, beta-Catenin, RB, Smad 2/3, SRC (Cell
Signaling Technologies, Danvers, USA), ERK 1/2, NF-κB,
PCNA, Stat3 (Santa Cruz, Santa Cruz, USA), KLK3
(Sigma), JNK, PKC, PLCγ (Abcam, Cambridge, USA),
and pERK (R&D, Minneapolis, USA).
Antibody-mediated signal amplification on microarrays
Incubation with primary antibodies was carried out as
described in the previous section. All working steps forBrase et al. Proteome Science 2010, 8:36
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Figure 1 Overview antibody-mediated signal amplification. (a) Samples are dispensed using a microarrayer, target proteins are detected with 
highly specific antibodies and visualized by incubation with near-infrared dye-labeled secondary antibodies. Fast-Green FCF based normalization de-
fines a spot-specific normalization factor. (b) Using the antibody-mediated signal amplification assay (AMSA) the antibody-based target protein de-
tection step is followed by additional cycles of incubating with two different NIR-labeled species-specific secondary antibodies to increase the density 
of fluorescent signals. Both secondary antibodies were selected to recognize the respective other species.
Target protein
Target specific 
antibody
Labeled
detection antibody
IPAQ
Single lysate spot
Reverse phase 
protein array (RPPA)
(Raised in rabbit)
(Directed against target protein)
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(Directed against rabbit)  
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(Directed against goat)
Labeled amplification
antibody 1
Labeled amplification
antibody 2
(Raised in goat)
(Directed against rabbit)  
a
b AMSABrase et al. Proteome Science 2010, 8:36
http://www.proteomesci.com/content/8/1/36
Page 4 of 10
antibody-mediated signal amplification were integrated
into an automated procedure. A robotics protocol was
established to increase and simplify the throughput. The
96-channel head robot Biomek FXP (Beckmann Coulter,
Harbor Boulevard, USA) was used for all assay steps thus
reducing hands-on time and minimizing experimental
variation.
Anti-rabbit Alexa680-labeled (raised in goat) and anti-
goat Alexa680-labeled (raised in rabbit) antibodies (both
Invitrogen) were applied consecutively in a total of four
cycles (dilution 1:8,000). Anti-mouse Alexa680 labeled
(raised in goat) antibody was used in the first cycle for the
detection of primary antibodies raised in mouse. Second-
ary antibodies employed for signal amplification were
derived from commercial sources and of highest purity.
Slides were washed four times for 5 minutes between
automated incubation steps. Each secondary antibody
was incubated for 30 minutes.
Western Blot detection
SDS-Page and Western immunoblotting analyses were
performed using 5 to 20 μg protein lysate. Standard near
infrared detection was applied as described elsewhere
[20]. The protocol for antibody-mediated signal amplifi-
cation was adapted to a larger volume. Tyramide signal
amplification was carried out in parallel to compare
directly between both amplification methods. TSA Kit
#11 (Invitrogen) was employed according to the manu-
facturer's instructions. Endogenous peroxidase was
treated with 3% H2O2 for one hour. A 1:250 dilution of the
HRP conjugated secondary antibody was applied. Peroxi-
dase catalyzed signal amplification was carried out for 10
minutes and Streptavidin-Alexa680 (Invitrogen) was
incubated for 20 minutes.
Statistical analysis
Slides were scanned with the Odyssey NIR scanner (LI-
COR). Image analysis was carried out with GenePix-Pro
5.1 (Axon Instruments, Sunnyvale, USA). Spot intensity
was corrected for background and noise due to unspecific
antibody binding. Mean and SD were calculated for all
replicates. Data sets were analyzed within the statistical
computing environment R.
The detection limit was determined as follows: First,
the signal intensity mean of a certain dilution step has to
be greater than the sum of 2 x standard deviation (SD) of
S0 and the mean of S0 with S0 corresponding to the lowest
concentration of a dilution series. Thus, S0 was consid-
ered as background signal [21] ensuring a significant dif-
ference of signals from background. Second, in a dilution
series signals must increase continuously with increasing
proteins concentrations. The lowest concentration of a
certain serial dilution complying with both requirements
is defined as limit of detection (LOD). To sum up, the
detection limit corresponded to the smallest concentra-
tion of a certain serial dilution that can be distinguished
from the experimental background as well as from the
next higher concentration. A detection limit is a specific
measure for a specific detection antibody, detection
method, and a specific sample. The curve fitting model
and the normalization approach are described in detail in
Additional file 1.
Results
Optimizing AMSA to a robust and specific amplification 
method
Important experimental parameters such as blocking and
wash buffer composition, primary and secondary anti-
body concentration, and the effect of background reduc-
ing agents were analyzed systematically to establish a new
amplification approach for RPPA. For example, a spike-in
approach with recombinant JNK1 protein was employed
to assess the detection limit of the new amplification
method. Beforehand, the specificity of all antibodies used
in the amplifications steps was confirmed by probing
suitable controls printed on microarrays such as human
immunoglobulins and recombinant JNK protein. Signal
detection omitting the target specific anti-JNK1 antibody
yielded no signals (Additional file 1, figure 1a). Data also
demonstrated that species-specific antibodies used as
part of the amplification procedure did not cross react
with human immunoglobulins potentially present in clin-
ical samples of human origin. On the other hand, the
presence of human immunoglobulins was confirmed by
probing a replicate slide with anti-human IgG antibody
Figure 2 Optimizing number of amplification cycles. Twelve repli-
cate spots of a colon cancer cell line containing 35 fg pERK were print-
ed on nitrocellulose-coated slides. Detection of pERK was performed 
by standard near-infrared detection and AMSA comprising different 
rounds of amplification. Median fluorescence (black) and signal-to-
noise ratios (red) were calculated. The blue line summarizes the results 
for AMSA optimization.Brase et al. Proteome Science 2010, 8:36
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Figure 3 Comparing standard NIR detection and AMSA. (a) Western blot specificity of TSA and AMSA. Detection of PSA (star-symbol) using stan-
dard NIR procedure (scan intensity 5), antibody-mediated signal amplification (scan intensity 2.5) and TSA (scan intensity 2.5). Each lane corresponds 
to loading 5 μg total protein from prostate cancer tissue or PSA-free negative controls: Colon cancer cell lines HT29 (1), SW480 (2), mouse liver lysate 
(3), and prostate cancer tissue (4). (b) Western blot analysis of 14 proteins in seven human cancer cell lines with standard NIR detection. (c) Samples 
were analyzed by RPPA to compare standard NIR detection and AMSA using the same set of antibodies as shown for the Western blot. The correlation 
analyses were based on log signal intensities.
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(Additional file 1, figure 1b), and the specificity of the
JNK1-detection was demonstrated as well (Additional file
1, figure 1c).
As a side-effect of signal amplification an increase of
background signal was supposed. Therefore, the AMSA-
dependent background signal gain was quantified using a
spike-in of phosphorylated recombinant ERK1. This way,
the best trade-off between specific and background signal
intensity gain was assessed. RPPA signal detection was
based on standard NIR or AMSA with one to five rounds
of signal amplification (Figure 2). Thus, background sig-
nal intensity gain correlated with the number of amplifi-
cation steps performed. After the first two cycles of
amplification signal-to-noise ratios were not improved
compared to those obtained by standard NIR detection.
However, after three amplification cycles the signal-to-
noise ratio started to increase and the best result was
obtained by carrying out four amplification cycles and
this number of cycles was consequently chosen as basis
for the AMSA procedure.
The specificity of the AMSA approach was validated by
detecting PSA in different samples on Western blots (Fig-
ure 3a) and compared to blots detected in parallel by
standard NIR and TSA-based signal amplification. In
detail, the presence of PSA was probed in a human pros-
tate cancer lysate and in samples serving as PSA-free neg-
ative controls such as human colon cancer cell lines
(HT29, SW480) or homogenized mouse liver. Strong and
specific PSA signals were detected only in prostate cancer
samples and when using standard NIR detection and
AMSA. The TSA detection yielded also a strong PSA
band on Western Blots. Nonetheless, several additional
bands were observerd in prostate tumor samples as well
as for the mouse liver lysates. To sum up, unspecific
bands were not observed in cell line samples and when
using standard NIR detection or AMSA. Thus, the
numerous additional bands emerging during the TSA
procedure were also observed when the anti-PSA anti-
body was omitted (data not shown) and possibly resulted
from insufficient masking of biotin proteins as artifact of
the TSA detection.
Aiming at a more comprehensive validation for a larger
set of target proteins 14 highly expressed signaling pro-
teins (CDK4, CyclinD1, ERK1/2, GSK, NF-κB, PCNA,
PKC, PLCy, PP2AA, PP2AB, RB, SMAD2/3, SRC,
STAT3) were chosen. Western blot analysis confirmed
that all proteins are indeed expressed in the human can-
cer cell lines (Figure 3b). The samples were also printed
on nitrocellulose-coated slides and probed with the same
set of primary antibodies to compare standard NIR
detection with antibody-mediated signal amplification
for RPPA. The subsequent data analysis revealed a strong
correlation between both data sets validating AMSA as
robust and reproducible (Pearson r = 0.89, p < 2.2-16) (Fig-
ure 3c).
Comparison of AMSA to NIR-standard detection for the 
detection of low abundance proteins
To test the advantage of AMSA also for the detection of
rare proteins, serial dilutions of recombinant JNK protein
Figure 4 Comparing the sensitivity of standard NIR detection and AMSA for JNK spike-in. Dilution series of JNK (0.27 fg - 0.56 pg JNK per spot) 
in a colon cancer cell line lysate. Each dilution step was printed in 12 replicate spots. Samples were analyzed using standard NIR detection and AMSA 
on two-pad slides in parallel. Slides were scanned at intensity 5 on the Odyssey instrument. Vertical red lines indicate the calculated detection limits.
Standard                   AMSA  Brase et al. Proteome Science 2010, 8:36
http://www.proteomesci.com/content/8/1/36
Page 7 of 10
were printed to determine the limit of detection (LOD)
for AMSA and for standard NIR. A mixture of three
human colon cancer cell lines (HT29, SW480, RKO) was
used as matrix to prepare a 12-step JNK dilution series.
All samples were printed in twelve replicate spots on 2-
pad nitrocellulose-coated glass slides to compare both
detection methods on a single slide. A curve fitting model
(Additional file 1) was employed to analyze the raw data
indicating an 8-fold lower limit of detection for AMSA
when compared to standard detection: 0.55 femtogram
JNK were detected per spot compared to 4.4 fg JNK per
spot for standard NIR (Figure 4). Moreover, a sensitive
discrimination even between small target protein differ-
ences was possible due to the improved linear range of
antibody-mediated signal amplification.
The general benefit of AMSA for the quantification of
low abundance proteins was evaluated further using a set
of eleven cancer cell lines. Cell line lysate samples were
printed as 14-step serial dilutions and in two subarrays
per slide. The first subarray was detected using standard
NIR, the other with AMSA. The slides were scanned at
different scanner sensitivity settings reflecting the fact
that the AMSA detection generally produces stronger
signals than the standard NIR detection. Thus, subarray
images produced with scanner settings optimal for the
AMSA readout, the corresponding subarray of the stan-
dard NIR detection was too dim to allow a reasonable
comparison between both methods. For this reason, each
slide was scanned at different scanner settings and for the
direct comparison between standard NIR and AMSA
images with comparable signal intensities were chosen
(Figure 5). Results indicated that the detection of low
abundant proteins indeed benefited from AMSA, as
shown for the detection of beta-Catenin and PDK1. The
limit of detection increased up to ten dilution steps for
beta-Catenin, and PDK1 (Figure 5). However, when cal-
culating the average LOD gain for all eleven cell lines a
mean LOD gain of 4- and 5-fold was observed for beta-
Catenin, and PDK1, respectively (Figure 6). The detection
of abundant proteins such as PCNA did not benefit from
AMSA (Figure 5 and 6). Thus, AMSA improved espe-
cially the detection of proteins expressed at a low level by
Figure 5 Comparing the sensitivity of standard NIR detection and AMSA for endogenous proteins. Detection of beta-Catenin, PDK1, and PCNA 
in the human colon cancer cell line HT-29 and in the human breast cancer cell lines T47D and MCF7 comparing AMSA with standard NIR. The limit of 
detection is indicated as red or blue line.
T47D
HT29
Beta-Catenin PDK1
MCF7
PCNABrase et al. Proteome Science 2010, 8:36
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reducing the scattering of weak signals and improving
signal-to-noise ratios. Antibody-mediated signal amplifi-
cation strategies promise to be useful for the RPPA-based
quantitative analysis of systems-biology type of experi-
ments as well as for the analysis of clinical samples.
Discussion
Reverse phase protein microarray techniques allow for a
highly parallel and quantitative analysis of signal trans-
duction processes requiring only minute amounts of
sample material. However, the protein of interest is fre-
quently expressed at a low level and its detection requires
highly sensitive methods. For this reason, a new NIR fluo-
rescence-based amplification approach was developed
[8,9]. To our knowledge, this is the first description of an
amplification system using successive incubation steps
with two species-specific secondary antibodies on pro-
tein microarrays.
Analyzing the expression level of 14 different proteins
with moderate to high abundance in seven different
human cancer cell lines by RPPA revealed that AMSA
results corresponded to those obtained with standard
NIR detection. Thus, the high correlation coefficient
indicated that the signal intensity gain mediated by
AMSA is reproducible. Furthermore, side-effects such as
background signal intensity gain were analyzed with
respect to the number of amplification cycles. Signal-to-
noise ratios improved considerably after three amplifica-
tion cycles, and four rounds of amplification were found
to deliver the best result. Thus, after four amplification
cycles the target specific signal intensity gain was higher
than the increase of the local background. Moreover, a
direct comparison between AMSA and standard NIR
confirmed a lower detection limit for a specific protein
spiked into a cell lysate as well as for endogenous proteins
expressed at a low level.
Different types of signal detection strategies were
reported for protein microarray applications. Colorimet-
ric, chemiluminescence, fluorescence detection tech-
niques, linear waveguide technologies [22], and rolling
circle amplification [23] were so far successfully adapted
to protein microarrays. Tyramide signal amplification is
one of the most frequently used techniques to increase
the sensitivity of reverse phase arrays. TSA is based on
the catalyzed deposition of tyramide in close proximity of
the secondary HRP-linked antibody [24,25]. The high
velocity of enzymatic processes was suspected to cause
signal saturation effects [26] and observed as sigmoidal
curves in serial dilutions limiting the signal detection
range on RPPA [7,27]. However, time-resolved measure-
ments involving systems biology applications benefit
from a linear correlation between sample concentration
and signal intensity. Besides that, insufficient specificity
has been reported for tyramide signal amplification strat-
egies [19,28]. Ambroz et al. suggested that identical
detection chemistries should be used for the RPPA-based
analysis and for Western blot based antibody validation
measures to reduce the risk of experimental artifacts [17].
Western blot detection indicated that indeed the use of a
biotin/avidin-based signal amplification strategy pro-
duces unspecific bands presumably due to insufficient
blocking of endogenous biotin-modified proteins. Biotin-
Figure 6 Comparing detection limits (LOD) between standard NIR detection and AMSA LOD for the detection of beta-Catenin, PDK1 and PCNA 
in eleven human cancer cell lines (SW480, HCT15, HCT116, SW620, HT29, T47D, BT474, MDA, SKBR3, HCC1954, MCF7) comparing AMSA with standard 
detection. The LOD is represented by the relative dilution step.
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modifications were identified on histones and presum-
ably play a role in epigenetic mechanisms [29]. However,
the use of AMSA circumvents the optimization of biotin-
blocking procedures since no unspecific background sig-
nals were observed.
Conclusions
We have shown that antibody-mediated signal amplifica-
tion is a powerful tool for the specific and sensitive detec-
tion of signals on reverse phase protein microarrays over
a large linear range. AMSA is easy to implement and
could in principle be also adapted to other immunoassay
formats. In addition, assay costs are low compared to
commercial amplification strategies since only low con-
centrations of secondary antibodies are required as
reagents.
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